MUDr. Jiří Tomášek, Ph.D.
Assistant professor, Comprehensive Cancer Care Department
Total number of publications: 208
2013
-
REGARD PHASE 3, RANDOMIZED TRIAL OF RAMUCIRUMAB IN PATIENTS WITH METASTATIC GASTRIC OR GEJ ADENOCARCINOMA FOLLOWING PROGRESSION ON FIRST-LINE CHEMOTHERAPY
Year: 2013, type: Appeared in Conference without Proceedings
-
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Year: 2013, type: Appeared in Conference without Proceedings
-
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy
Year: 2013
-
Regorafenib
Farmakoterapie, year: 2013, volume: 2013, edition: 2, DOI
-
Současný přístup k léčbě pacientů s metastatickým kolorektálním karcinomem
Vnitřní lékařství, year: 2013, volume: 59, edition: 10
-
Systémová protinádorová léčba kolorektálního karcinomu.
Onkologie, year: 2013, volume: 7, edition: 4
-
The liver function assessment – The indocyanine green retention in correlation with the cholescintigraphic measurement: A retrospective validation study in 107 patients with liver malignancies.
Year: 2013, type: Appeared in Conference without Proceedings
2012
-
Biologická léčba gastroenteropankreatických neuroendokrinních tumorů
Sborník témat a přednášek XVII. den profesora Vladimíra Staška, year: 2012
-
Diseminovaný kolorektální karcinom. Strategie léčby.
Year: 2012, edition: Vyd. 1., number of pages: 76 s.
-
Epidemiologie, prevence a léčba kolorektálního karcinomu dle dostupných českých a mezinárodních dat
Year: 2012, edition: Vydání 1., number of pages: 199 s.